Moberg Pharma AB | Balance Sheet

Fiscal year is January-December. All values SEK Millions.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
27
62
45
86
119
111
Total Accounts Receivable
23
37
45
80
77
73
Inventories
7
13
22
42
27
25
Other Current Assets
3
5
6
13
10
3
Total Current Assets
59
117
119
221
233
212
Net Property, Plant & Equipment
1
1
1
1
1
-
Total Investments and Advances
-
-
-
-
-
-
Intangible Assets
182
216
261
1,000
980
1,034
Total Assets
272
360
397
1,232
1,223
1,252
ST Debt & Current Portion LT Debt
13
13
3
-
-
Accounts Payable
5
7
15
16
25
Other Current Liabilities
34
33
26
59
48
Total Current Liabilities
52
53
45
75
74
Long-Term Debt
17
3
-
589
592
Deferred Taxes
27
25
16
3
4
Total Liabilities
70
56
45
671
671
Common Equity (Total)
201
304
353
562
552
Total Shareholders' Equity
201
304
353
562
552
Total Equity
201
304
353
562
552
Liabilities & Shareholders' Equity
272
360
397
1,232
1,223

About Moberg Pharma AB

View Profile
Address
Gustavslundsvägen 42, 5 tr
Bromma AB 167 51
Sweden
Employees -
Website http://www.mobergpharma.se
Updated 07/08/2019
Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. It offers its products through the following brands: Kerasal, Kerasal Nail, Balmex, NewSkin, Dermoplast, Domeboro, and Fiber Choice. The company was founded by Peter Gunnar Maurits Wolpert and Marie Moberg in March 2006 and is headquartered in Bromma, Sweden.